Abiopharma

🔍 Tighe Brett (Executive)

Company: Okta, Inc. (OKTA)

Report Date: 2026-06-08

Detailed Transactions and Holdings:

• Sold 28,548 shares of Class A Common Stock at $116.6656 per share (Direct)
  Date: 2026-06-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 156,132.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 34,152 shares of Class A Common Stock at $117.6537 per share (Direct)
  Date: 2026-06-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 121,980.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,300 shares of Class A Common Stock at $118.5244 per share (Direct)
  Date: 2026-06-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 119,680.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-08 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 1,250.00
• Holds 15,494 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: H | shares_owned_after: 15,494.00 | Footnotes: F4, F5, F5
• Holds 28,160 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: H | shares_owned_after: 28,160.00 | Footnotes: F4, F6, F6
• Holds 55,426 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-08 | Code: H | shares_owned_after: 55,426.00 | Footnotes: F4, F7, F7
• Holds 69,046 shares of Class B Common Stock (Derivative)
  Date: 2026-06-08 | Code: H | shares_owned_after: 69,046.00 | Footnotes: F8, F8, F8

Footnotes:

• F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.11 to $117.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.11 to $118.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.11 to $119.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Class A Common Stock.
• F5: 8.33% of the shares underlying the RSU vested on June 15, 2024, and the remaining shares underlying the RSU shall vest in 11 equal quarterly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer on each such date.
• F6: 8.33% of the shares underlying the RSU vested on June 15, 2025, and the remaining shares underlying the RSU shall vest in 11 equal quarterly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer on each such date.
• F7: 8.33% of the shares underlying the RSU shall vest on June 15, 2026, and the remaining shares underlying the RSU shall vest in 11 equal quarterly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer on each such date.
• F8: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.